Shares of Icon Plc (NASDAQ:ICLR) have been assigned a consensus rating of “Buy” from the twelve ratings firms that are currently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $96.00.
ICLR has been the subject of several recent research reports. Mizuho initiated coverage on shares of Icon Plc in a research report on Thursday, March 23rd. They issued a “neutral” rating and a $66.00 target price for the company. Zacks Investment Research downgraded shares of Icon Plc from a “hold” rating to a “sell” rating in a research report on Wednesday, April 26th. Evercore ISI boosted their target price on shares of Icon Plc from $91.50 to $92.00 and gave the stock an “outperform” rating in a research report on Friday, April 28th. Jefferies Group LLC reissued a “hold” rating on shares of Icon Plc in a research report on Thursday, May 11th. Finally, ValuEngine downgraded shares of Icon Plc from a “buy” rating to a “hold” rating in a research report on Wednesday, May 31st.
Several hedge funds have recently bought and sold shares of ICLR. Somerset Trust Co increased its stake in Icon Plc by 8.0% in the second quarter. Somerset Trust Co now owns 6,087 shares of the medical research company’s stock valued at $595,000 after buying an additional 449 shares in the last quarter. GW&K Investment Management LLC increased its stake in Icon Plc by 29.1% in the second quarter. GW&K Investment Management LLC now owns 9,421 shares of the medical research company’s stock valued at $921,000 after buying an additional 2,121 shares in the last quarter. Atria Investments LLC increased its stake in Icon Plc by 9.3% in the second quarter. Atria Investments LLC now owns 2,940 shares of the medical research company’s stock valued at $288,000 after buying an additional 251 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in Icon Plc during the second quarter valued at about $626,000. Finally, Clearbridge Investments LLC increased its stake in Icon Plc by 45.2% in the first quarter. Clearbridge Investments LLC now owns 1,594,656 shares of the medical research company’s stock valued at $127,126,000 after buying an additional 496,700 shares in the last quarter. 92.64% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Icon Plc (NASDAQ:ICLR) Receives Consensus Rating of “Buy” from Analysts” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/07/17/icon-plc-nasdaqiclr-receives-consensus-rating-of-buy-from-analysts.html.
Shares of Icon Plc (NASDAQ:ICLR) traded down 0.10% during midday trading on Monday, reaching $99.22. 186,601 shares of the company were exchanged. The company’s 50-day moving average price is $93.54 and its 200 day moving average price is $84.14. Icon Plc has a 52-week low of $70.06 and a 52-week high of $100.86. The stock has a market capitalization of $5.34 billion, a price-to-earnings ratio of 20.59 and a beta of 0.59.
Icon Plc (NASDAQ:ICLR) last posted its earnings results on Thursday, April 27th. The medical research company reported $1.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.27 by $0.02. The company had revenue of $432 million during the quarter, compared to the consensus estimate of $432.21 million. Icon Plc had a net margin of 16.15% and a return on equity of 28.89%. The company’s revenue for the quarter was up 7.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.12 earnings per share. On average, equities analysts predict that Icon Plc will post $5.17 earnings per share for the current year.
Icon Plc Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
What are top analysts saying about Icon Plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Icon Plc and related companies.